PARP1 and acute myeloid leukemia: Recent studies have shown that inhibition of FLT3(ITD) activity by quizartinib downregulated the DNA repair proteins and indicated that quizartinib sensitized FLT3(TID)-positive AML cells to synthetic lethality triggered by PARP inhibitors via inhibition of the DSB repair pathways.